在荷尔蒙疗法中添加abemaciclib或ribocciclib可以提高存活率,并减少高风险早期乳腺癌的复发。 Adding abemaciclib or ribociclib to hormone therapy improves survival and reduces recurrence in high-risk early breast cancer.

对PampeantE试验进行的一项新分析表明,在内分泌疗法中增加abemaciclib可大大改善高危荷尔蒙受体阳性、HER2-阴性早期乳腺癌的总体存活率,在7年中将死亡风险降低15.8%,使其成为第一个展示这一好处的抑制因素。 A new analysis of the monarchE trial shows that adding abemaciclib to endocrine therapy significantly improves overall survival in high-risk hormone receptor-positive, HER2-negative early breast cancer, reducing the risk of death by 15.8% over seven years, making it the first CDK4/6 inhibitor to show this benefit. 与此同时,NATALEE试验的五年数据证实,将利博西基利布与芳香酶抑制剂结合使用可提高无侵袭性疾病的生存率,并降低远期复发风险,没有新的安全问题. Meanwhile, five-year data from the NATALEE trial confirm that combining ribociclib with an aromatase inhibitor boosts invasive disease-free survival and reduces distant recurrence risk, with no new safety concerns. 这两种治疗都为高风险病人,包括患结点阴性疾病的病人提供长期福利,并支持使用CDK4/6抑制剂作为标准的辅助疗法。 Both treatments offer long-term benefits for high-risk patients, including those with node-negative disease, and support the use of CDK4/6 inhibitors as standard adjuvant therapy.